Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
IDH2 mutation + NTRK3 fusion
Cancer:
Astrocytoma
Drug:
Rozlytrek (entrectinib)
(
ALK inhibitor
,
TrkB receptor inhibitor
,
TrkC kinase inhibitor
,
TrkA receptor inhibitor
,
ROS1 inhibitor
,
JAK2 inhibitor
,
TNK2 inhibitor
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
NCCN
Excerpt:
ADULT GLIOMA: IDH-MUTANT ASTROCYTOMA….Recurrent or Progressive Disease WHO grade 2, KPS ≥60...Useful in Certain Circumstances...NTRK gene fusion tumors...Entrectinib
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login